Overview
Huma (formerly Medopad) has evolved into a leading global health technology platform, serving as a comprehensive 'hospital-at-home' and decentralized clinical trial solution. By 2026, the platform has solidified its position as a Software as a Medical Device (SaMD) powerhouse, leveraging advanced AI to identify subtle changes in patient physiology. Its technical architecture is built on the Huma Cloud Platform, which integrates real-world data from wearable devices, patient-reported outcomes, and clinical-grade sensors. Huma utilizes proprietary AI algorithms and digital biomarkers—such as voice analysis for respiratory health and gait analysis for neurological conditions—to provide predictive insights that allow for early intervention. The platform is highly modular, offering disease-specific configurations for oncology, cardiology, and rare diseases. In 2026, Huma’s integration of Generative AI (via its partnership with Google Cloud) enables automated clinical documentation and personalized patient engagement at scale, bridging the gap between traditional clinical settings and continuous, home-based monitoring.